@entity1557 is a common cause of breast lump in young @entity1 . Nearly 10-15  % of lesions regress spontaneously over the period of 6 to 60  months. The aim of study was to investigate the role of Centchroman in regression of @entity1557 in comparison to natural observation and to study the association of hormonal receptors with degree of regression. The study was carried out at the outpatient clinic of Department of Surgery, All India Institute of Medical Sciences, New Delhi, from November 2004 to November 2007. @entity1 aged  <=30  years with @entity1557 were included. @entity1 with @entity1557 equal to or larger than 5  cm and with @entity2670 were excluded. @entity1 were randomized in two groups. @entity1 in active therapy arm were prescribed Centchroman 30  mg daily for 12  weeks, and another group was observed without any intervention (control group). @entity1 were followed at weeks 4, 8, 12, and 24 to assess response to therapy. Twenty-two (31.88  %) @entity1557 in Centchroman arm disappeared completely as compared to four (7.69  %) in control arm over a period of 6  months. There was a decrease in the volume of @entity1557 in ten (19.23  %) @entity1 in control arm and 36 (52.17  %) @entity1 in Centchroman arm. Centchroman therapy allowed 31  % @entity1557 to regress completely with scanty menses or @entity2588 as the only side effect.

Regression of XXXX with Centchroman: a Randomized Controlled Trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'girls'] @entity2588 :: ('MESH:D000568', 'Disease') :: ['amenorrhea'] @entity2670 :: ('MESH:D010049', 'Disease') :: ['polycystic ovarian disease'] @entity1557 :: ('MESH:D018226', 'Disease') :: ['Fibroadenoma', 'fibroadenomas', 'fibroadenoma']
@entity1557 :: (MESH:D018226,Disease) :: ['Fibroadenomas']
